Document Detail

Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden.
MedLine Citation:
PMID:  7515649     Owner:  NLM     Status:  MEDLINE    
Two hundred fifty-nine previously untreated patients with low-grade non-Hodgkin's lymphomas (NHLs), Ann Arbor stages III and IV, entered a randomized multicenter trial comparing the therapeutic effect of chlorambucil/prednisone (ChP) vs. CHOP. All patients had symptomatic disease. The therapeutic aim was to achieve an asymptomatic state in the ChP group (n = 132), while in CHOP-treated patients (n = 127) the intention was to reach a complete remission (CR). The response rate (CR+PR at 8 months) was 36% in the ChP and 60% in the CHOP group (p < 0.01). Three and 5-year survival rates were 59% and 41% in the ChP group and 64% and 44% in the CHOP group. The corresponding median survival times were 46 and 52 months. After correction for intercurrent deaths, the overall 5-year survival was 49% for ChP and 54% for CHOP-treated patients. The differences were statistically not significant. The time from diagnosis to randomization (time with asymptomatic disease) was longer than one year in half of the patients. The median survival time from diagnosis was 68 months, with no differences between the treatment groups. In all histological subgroups (CLL, IC, CC, and CB-CC), a higher remission rate was seen with the CHOP regimen but with no statistically significant influence on survival. Comparing patients below and above 65 years of age, no significant difference in survival was noted between the two treatment groups. The results do not support the use of intensive chemotherapy as first-line therapy in symptomatic low-grade NHL.
E Kimby; M Björkholm; G Gahrton; B Glimelius; H Hagberg; B Johansson; H Johansson; G Juliusson; M Järnmark; E Löfvenberg
Related Documents :
21975389 - Prognostic impact of standardized uptake value of f-18 fdg pet/ct in nasopharyngeal car...
11785839 - Infusional cde with rituximab for the treatment of human immunodeficiency virus-associa...
17326249 - Long-term outcome after prophylactic lamivudine treatment on hepatitis b virus reactiva...
10052709 - Idec-c2b8 anti-cd20 (rituximab) immunotherapy in patients with low-grade non-hodgkin's ...
22126559 - Survival and prognostic factors comparing stage ib 1 versus stage ib 2 cervical cancer ...
11224599 - Pathologic and clinical features of 77 hodgkin's lymphoma patients treated in a lymphom...
2449159 - Adjuvant cytotoxic chemotherapy following wertheim radical hysterectomy for cervical ca...
10774569 - Mitoxantrone, 5-fluorouracil and low-dose leucovorin in doxorubicin-resistant advanced ...
8278179 - Combined local excision and brachytherapy with ruthenium-106 in the treatment of epibul...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  5 Suppl 2     ISSN:  0923-7534     ISO Abbreviation:  Ann. Oncol.     Publication Date:  1994  
Date Detail:
Created Date:  1994-07-12     Completed Date:  1994-07-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  67-71     Citation Subset:  IM    
Dept of Medicine, Danderyd Hospital, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Actuarial Analysis
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Cause of Death
Chlorambucil / administration & dosage
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Lymphoma, Non-Hodgkin / drug therapy*,  mortality
Middle Aged
Palliative Care*
Prednisone / administration & dosage
Remission Induction
Survival Analysis
Treatment Outcome
Vincristine / administration & dosage
Reg. No./Substance:
0/CHOP protocol; 0/COP protocol 2; 23214-92-8/Doxorubicin; 305-03-3/Chlorambucil; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's dise...
Next Document:  Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and r...